Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Precision medicine is one of the most talked about trends in healthcare. The promise is improved health outcomes and patient satisfaction, gained through an understanding of individual variability in genes, environment, and lifestyle. Recent commentators suggest that many of the technologies required to realize this goal already exist—and predict much
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery.
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
